Oxichemo 100mg Infusion

Introduction

Oxichemo is a prescription medication that contains the active ingredient Oxaliplatin. It is commonly used in the treatment of certain types of cancer, including colorectal cancer and advanced gastric cancer.

Uses

Oxichemo is primarily prescribed for the treatment of colorectal cancer and advanced gastric cancer. It is often used in combination with other chemotherapy medications to help slow down or stop the growth of cancer cells.

Dosage and Administration

The dosage of Oxichemo will vary depending on the specific type and stage of cancer being treated, as well as individual patient factors. It is administered intravenously (into a vein) by a healthcare professional in a hospital or clinic setting. The infusion is typically given over a specific period of time, usually every two to three weeks. Your healthcare provider will determine the appropriate dosage and treatment schedule for you.

Mechanism of Action

Oxaliplatin, the active ingredient in Oxichemo, belongs to a class of medications called platinum-containing compounds. It works by interfering with the DNA in cancer cells, preventing them from dividing and growing. This helps to slow down or stop the growth of cancer cells, reducing the size of tumors and potentially improving outcomes for patients.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, fatigue, and peripheral neuropathy (numbness or tingling in the hands and feet). These side effects are usually temporary and can be managed with medications or other supportive care measures. However, if you experience any severe or persistent side effects, contact your healthcare provider immediately.

Drug Interactions

Oxichemo may interact with other medications, including certain pain medications, anticonvulsants, and vaccines. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. They can help determine if any potential drug interactions may occur and adjust your treatment plan accordingly.

Precautions

Before starting treatment with Oxichemo, inform your healthcare provider about any allergies, medical conditions, or medications you are currently taking. This medication may not be suitable for everyone, especially those with a history of allergic reactions to platinum-containing compounds or certain other medications. Avoid becoming pregnant or fathering a child while receiving treatment with Oxichemo, as it may cause harm to an unborn baby.

Storage

Oxichemo should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). It should be kept in its original packaging and protected from light. Do not freeze the medication. If you have any concerns about the storage of your medication, consult your healthcare provider or pharmacist.

Patient Tips

• Follow the instructions provided by your healthcare provider regarding the administration of Oxichemo.
• Stay hydrated and maintain a healthy diet during treatment to help manage side effects.
• Report any unusual or severe side effects to your healthcare provider immediately.
• Keep all scheduled appointments for chemotherapy treatments and follow-up visits.
• If you have any questions or concerns about your treatment with Oxichemo, do not hesitate to reach out to your healthcare provider for assistance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Oxaliplatin 5 mg/ml concentrate for solution for infusion (Health Professionals SmPC) Available at:
• Oxaliplatin (Drugs.com) [Accessed 23 Jun. 2024] (online) Available at:
• oxaliplatin vial (RX) [Accessed 30 Jun. 2024] (online) Available at:
• Oxaliplatin Injection (MedlinePlus) [Accessed 14 Jun. 2024] (online) Available at:
• Shi Y, Niu Y, Yuan Y, Li K, Zhong C, Qiu Z, Li K, Lin Z, Yang Z, Zuo D, Qiu J, He W, Wang C, Liao Y, Wang G, Yuan Y, Li B. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun. 2023 Apr 6;14(1):1932. doi: 10.1038/s41467-023-37542-5. [Accessed 11 Jun. 2024] Available at: